19,161 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 19,161 shares of the specialty pharmaceutical company’s stock, valued at approximately $572,000. Advantage Alpha Capital Partners LP owned approximately 0.06% of Collegium Pharmaceutical as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Fuller & Thaler Asset Management Inc. boosted its position in Collegium Pharmaceutical by 1.4% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,371,448 shares of the specialty pharmaceutical company’s stock valued at $40,938,000 after purchasing an additional 19,568 shares during the last quarter. Emerald Advisers LLC boosted its position in Collegium Pharmaceutical by 1.8% during the first quarter. Emerald Advisers LLC now owns 826,475 shares of the specialty pharmaceutical company’s stock valued at $24,670,000 after purchasing an additional 14,795 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in Collegium Pharmaceutical by 18.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company’s stock valued at $21,309,000 after purchasing an additional 109,655 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in Collegium Pharmaceutical by 0.8% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 574,080 shares of the specialty pharmaceutical company’s stock valued at $17,136,000 after purchasing an additional 4,513 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Collegium Pharmaceutical by 5.6% during the fourth quarter. Northern Trust Corp now owns 385,157 shares of the specialty pharmaceutical company’s stock valued at $11,035,000 after purchasing an additional 20,490 shares during the last quarter.

Insider Activity

In other news, Director John Gordon Freund sold 11,659 shares of the company’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $34.36, for a total transaction of $400,603.24. Following the completion of the sale, the director directly owned 23,129 shares in the company, valued at approximately $794,712.44. This represents a 33.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gino Santini sold 5,405 shares of the company’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $37.19, for a total value of $201,011.95. Following the sale, the director owned 95,042 shares of the company’s stock, valued at approximately $3,534,611.98. The trade was a 5.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 44,915 shares of company stock worth $1,614,825. 2.51% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $39.52 on Friday. The stock has a fifty day moving average price of $32.22 and a 200-day moving average price of $30.00. The company has a market cap of $1.24 billion, a price-to-earnings ratio of 38.00 and a beta of 0.68. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.10 and a current ratio of 1.18. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29.

Collegium Pharmaceutical declared that its Board of Directors has initiated a stock buyback plan on Monday, July 7th that allows the company to repurchase $150.00 million in outstanding shares. This repurchase authorization allows the specialty pharmaceutical company to buy up to 15.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

Several research analysts recently commented on the company. Piper Sandler reissued a “neutral” rating and set a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Finally, HC Wainwright raised Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price target for the company in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $42.33.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.